- EMA decision on anakinra could be a gamechanger
- Launch of POC+ product is around the corner
- We maintain our valuation interval of
DKK 115.00 – 180.00 per share
ViroGates’ report for Q2 did not contain any surprises. The reported financial data is of second-order importance anyway to the big event later in the autumn. In October, EMA is expected to decide on a possible label extension for anakinra, a potentially life-saving treatment for severe COVID-19 pneumonia cases. The label extension would mean approval for suPAR-guided screening to select patients for anakinra treatment, and this would imply very interesting market opportunities for
The full report is available here.
© Modular Finance, source